Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and MLL-Rearranged Leukemia Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DOT1L drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DOT1L Recombinant Active Domain Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for methyltransferase assays. |
View DOT1L Products |
| Gene Delivery | DOT1L Promise-ORF / Lentivirus Full-length ORF for stable cell lines and target engagement assays. |
View DOT1L Products |
| Benchmark Ab | Anti-DOT1L / Anti-H3K79me2 Recombinant Antibodies Recombinant positive controls for chromatin immunoprecipitation (ChIP) and Western Blot. |
View DOT1L Products |
| Validator | DOT1L siRNA Set For target knockdown and specificity validation in phenotypic assays. |
View DOT1L Products |
| Related Target A | KMT2A (MLL1) Crucial partner in MLL-rearranged leukemogenesis; synergizes with DOT1L inhibition. |
View KMT2A Products |
| Related Target B | MEN1 (Menin) Interacts with the MLL complex; co-targeting Menin and DOT1L represents a major therapeutic strategy. |
View MEN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity screening against other histone methyltransferases (HMTases) | Homolog panel proteins (EZH2, G9a, SUV39H1) strictly verified by mass spectrometry and sequence analysis. |
| High-throughput SAM-competitive binding assays | Sf9 insect cell or E. coli expressed catalytic domains with optimized purity (>95%) and theoretical MW verification. |
| Lack of reliable positive control antibodies | Sequence-defined clinical benchmark antibodies and epigenetic-specific reference antibodies included. |
| Off-target assay artifacts | Sequence-verified siRNA sets included for genetic validation and target knockdown controls. |
Live DOT1L/HLNM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The development of therapeutics targeting DOT1L (disruptor of telomeric silencing 1-like, also known as HLNM) remains a highly specialized and critical frontier in epigenetic drug discovery. Primarily characterized as the sole methyltransferase responsible for histone H3 lysine 79 (H3K79) methylation, DOT1L is a major driver in mixed-lineage leukemia (MLL)-rearranged (KMT2A-rearranged) and NPM1-mutant acute myeloid leukemias.
The race for DOT1L therapeutics is intensifying, with major players shifting focus from traditional monotherapies to rational combination regimens and next-generation small molecule inhibitors with improved pharmacokinetic profiles. As first-generation therapies like Pinometostat (EPZ-5676) reach clinical milestones, the next wave of R&D is targeting synergistic epigenetic networks, including Menin-MLL inhibitors and HDAC inhibitors, to overcome resistance and enhance therapeutic efficacy in solid tumors and hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Ipsen (Epizyme), Daiichi Sankyo, Syros Pharmaceuticals | MLL-rearranged Leukemia, NPM1-mutant AML | Enzymatic Methyltransferase Assays (Need high-purity catalytic domain and SAM-binding verification) |
| Combination Therapies (Menin/DOT1L) | Syndax Pharmaceuticals, Kura Oncology | Refractory Acute Leukemias | Synergy Validation (Need co-expression and interaction assays with MEN1 and KMT2A proteins) |
| PROTACs / Degraders | Academic institutions, Biotech startups | Advanced Solid Tumors, Hematological Malignancies | Target Engagement & Degradation Assays + H3K79me2 cellular quantification (Need Lentivirus for stable cell lines) |